Zai Lab partner MacroGenics announces US FDA approval of MARGENZA for patients with pretreated metastatic HER2-positive breast cancer

▴ Zai Lab partner MacroGenics announces US FDA approval of MARGENZA for patients with pretreated metastatic HER2-positive breast cancer
The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial

Zai Lab Limited’s partner MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is being further developed by MacroGenics for the treatment of advanced gastric cancer, with support by Zai Lab in Greater China. The approval in breast cancer in the U.S. was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

“We congratulate our partner MacroGenics for this great success,” said Samantha Du, PhD., Founder, Chairwoman and Chief Executive Officer of Zai Lab. “We look forward to bringing this important medicine to metastatic breast cancer patients in China as soon as possible. We are also participating in the global Phase 2/3 MAHOGANY clinical trial of margetuximab plus checkpoint blockade, with or without chemotherapy, as a potential first-line treatment for patients in front-line gastroesophageal cancer.”

The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial. The study, which included 536 patients, showed a statistically significant 24% reduction in the risk of disease progression or death with MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy (hazard ratio [HR]=0.76; 95% CI, 0.59-0.98; P=0.033; median PFS 5.8 vs 4.9 months). The objective response rate for MARGENZA plus chemotherapy was 22% and for trastuzumab plus chemotherapy was 16%. The final Overall Survival (OS) analysis is expected in the second half of 2021.

Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.

The SOPHIA study is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. All study patients had previously received trastuzumab, all but one patient had previously received pertuzumab, and 91% had previously received ado-trastuzumab emtansine, or T-DM1.

The study enrolled 536 patients who were randomized 1:1 to receive either MARGENZA (n=266) given intravenously at 15 mg/kg every three weeks or trastuzumab (n=270) given intravenously at 6 mg/kg (or 8 mg/kg for loading dose) every three weeks in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) given at the standard doses. Intent-to-treat PFS analysis occurred after 265 PFS events.

The primary endpoints of the study are sequentially assessed PFS, determined by blinded, centrally reviewed radiological review, followed by OS. Additional key secondary endpoints are PFS by investigator assessment, ORR and Duration of Response. Tertiary endpoints include ORR by investigator assessment and safety. PFS and ORR were assessed according to Response Evaluation Criteria in Solid Tumours version.

Tags : #ZaiLab #MacroGenics #LatestResearchonBreastCancer17thDec #LatestUSFDAApproval17thDec #LatestPharmaNews17thDec #BreastCancerandChemotherapy

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Our Brain's Hunger Games: How Mental Cravings Attack ImmunityApril 09, 2025
Inhale Anxiety, Exhale Joy: Is Air Pollution Ruining Mental Health?April 09, 2025
Are You Slowly Killing Your Brain: Habits That Steal Your Memory, Mood, and Mental StrengthApril 09, 2025
Baby & Mom Retail Launches it's New Healthcare Equipment Brand CORVELLApril 09, 2025
Wellbeing Nutrition unveils a new campaign with their Brand Ambassador, Sharvari, Celebrating the power of “Beauty Within”April 09, 2025
Given the rise in heart attack cases in womenApril 08, 2025
CARE Hospitals Marks World Health Day 2025 with ‘Walk for a Healthy Beginning’ at CharminarApril 08, 2025
Cancer, Obesity, Mental Health, India’s top health concerns: Ipsos Health Service Report 2024 April 08, 2025
Why Loneliness Might Be the Real Reason You're Always Falling SickApril 08, 2025
Is Your Beverage Choice Secretly Harming Your Mind?April 08, 2025
India’s Hidden Health Pandemic: Vitamin D Deficiency Affects One in FiveApril 08, 2025
Xavier University strengthens ties with India through strategic visitApril 08, 2025
Desire, Distraction, and Distress: The Untold Connection of ADHD and SexApril 08, 2025
Medical breakthrough unlocks rare disease discoveryApril 08, 2025
Elevate your space with the Crompton’s 3-star energy efficient, Avancer Swirl Ceiling Fan – a perfect combination of Aesthetics and Technology!April 07, 2025
CARE Hospitals Launches ‘SANGHAM’ Card on World Health DayApril 07, 2025
Sharda Care Healthcity partners with Prometheus School to strengthen awareness on healthy living among communities this World Health DayApril 07, 2025
Sharda Care Healthcity partners with Prometheus School to strengthen awareness on healthy living among communities this World Health DayApril 07, 2025
When the Fight Comes Back: Tahira’s Relapse and the Reality of Breast Cancer Beyond RecoveryApril 07, 2025
Beyond Hospitals and Hashtags: What World Health Day Should Really Teach UsApril 07, 2025